CA-PROSIMO
12.6.2024 16:01:30 CEST | Business Wire | Press release
Prosimo, a leader in multi cloud networking software [MCNS], today announced an integration with Palo Alto Networks for a powerful new approach to security that protects applications and workloads in multi cloud environments.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240612713674/en/
Hop by Hop Traceability Including the Packets Being Actioned Within a Firewall (Graphic: Business Wire)
With Prosimo’s Full Stack Cloud Transit platform, customers can seamlessly integrate with Palo Alto Networks VM-Series Virtual Next-Generation Firewall (NGFW), allowing enterprises to deploy security as close as possible to the workloads they protect. This architecture greatly reduces the time and effort required to secure application access across multi cloud environments for users and workloads.
“Together with Palo Alto Networks VM-Series virtual firewalls, we’re providing organizations with a Zero Trust framework so they can be confident their application workloads are secure while ensuring fast and reliable connectivity to and across cloud providers,” said Prosimo Vice President of Product Mani Ganesan. “This integration allows enterprises to improve observability, increase operational efficiency, and safely gives them more control of their cloud environment.”
Join the Office Hours to explore the use case and see a live demo here.
Most integrations today focus on orchestrating firewalls and inserting them in the path of cloud network traffic, where they rely on IP addresses/port numbers to redirect traffic. Prosimo instead provides service insertion policies that allow users to define sophisticated rules that determine which traffic will be routed for advanced inspection to the firewall.
Prosimo simplifies deployment for two flexible architectures for Palo Alto Networks VM-Series virtual firewalls:
- Centralized: VM-Series virtual firewall is deployed into a centralized VPC for east-west (VPC-to-VPC) or north-south (Internet egress and ingress, cloud to on-premises) traffic. This is the most common Prosimo model and provides security control and ongoing manageability.
- Distributed: VM-Series virtual firewalls are deployed in each virtual private cloud. This method is typically used in cases where VPCs need to be isolated and require local ingress or egress.
“Speed is critical in the cloud, so the speed of operations in configuring software firewalls, like the VM-Series virtual firewall, needs to match the speed of cloud deployments,” said Vitaliy Sivetskiy, senior product manager of Palo Alto Networks. “Integrating Prosimo’s Full Stack Cloud Transit and Palo Alto Networks VM-Series virtual firewall makes network security teams' lives easier. Our single intuitive operating model for connectivity and virtual firewall insertion means customers have more time to focus on application business innovation versus managing network and security infrastructure. This enables organizations to help protect all clouds, the right way, with agility.”
Providing Multi-Layer Security to Navigate Cloud Firewall Complexity
While a well-constructed multi cloud networking architecture can enhance security, scaling of firewalls can be complex. Common challenges include ensuring the virtual firewall can handle the required elasticity associated with growing cloud resources, managing complex network configurations for auto scaling, and implementing ongoing route updates to direct traffic through the next-generation firewall while maintaining segmentation and isolation.
Integrating Prosimo with Palo Alto Networks VM-Series virtual firewalls ensures enhanced security and scalability across the network and application layer. Palo Alto Networks Next-Generation Firewalls offer comprehensive Layer 7 inspection, while Prosimo stands out as a leading provider in the MCNS market capable of delivering network segmentation spanning Layer 3 to Layer 7.
With native integration, customers can provision new virtual firewalls in a few clicks. From a single dashboard, users can manage the lifecycle of those firewalls, quickly scaling up or down while segmenting the necessary subnets and corresponding cloud-native elements.
Customers can see immediate benefits from the integration through:
- Migrating to Palo Alto Networks software next-generation firewalls faster, eliminating blind spots for both network and security teams.
- Right-sizing software firewalls to optimize cloud costs.
- Using the existing firewall investment to segment east-west and north-south data movement within clouds.
Go to prosimo.io to learn how Prosimo and Palo Alto Networks enable enterprises to build, modernize, and future-proof cloud infrastructure.
About Prosimo
Prosimo delivers a simplified multicloud infrastructure for distributed enterprise cloud journeys. Companies innovate faster and remain in control with the Prosimo integrated stack. This stack combines cloud networking, performance, security, observability, and cost management—all powered by data insights and machine learning models with autonomous cloud networking to reduce complexity and risk. Cloud-forward enterprises, including F100, have successfully adopted Prosimo to roll out revenue-generating applications, improve operational efficiency, and accelerate positive business outcomes. Prosimo is venture-backed by marquee investors such as General Catalyst, WRVI Capital, and Blackrock. For more information, visit https://www.prosimo.io.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240612713674/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
